Top 10 Life Science Resources for Summer 2024
Alta Sciences
JULY 25, 2024
To ensure you're in the know, we've put together a summary of recent revisions, drafts, and final guidances from the FDA. Read the eBook.
Alta Sciences
JULY 25, 2024
To ensure you're in the know, we've put together a summary of recent revisions, drafts, and final guidances from the FDA. Read the eBook.
Agency IQ
MAY 3, 2024
What We Expect the FDA to do in May and June 2024 In this ongoing feature, AgencyIQ looks at public data to determine what the FDA is likely to do in the months ahead, including key deadlines, meetings, events, planned regulations, comment periods and more.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
JULY 4, 2023
These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. Patients and caregivers also assess the benefits offered by different therapies, weighing the progression-free survival with their off-target effects.
Agency IQ
JULY 8, 2024
What We Expect the FDA to do in July and August 2024 In this ongoing feature, AgencyIQ looks at public data to determine what the FDA is likely to do in the months ahead, including key deadlines, meetings, events, planned regulations, comment periods and more. We will see if FDA is willing to accept those changes later this month.
Alta Sciences
OCTOBER 30, 2023
TOP NONCLINICAL SCIENTIFIC RESOURCES eBook : Safety Assessment for Ophthalmic Products Designing preclinical studies for ocular therapies take a lot of deliberation. To ensure you're in the know, we've put together a summary of recent revisions, drafts, and new guidance releases from the FDA, EMA, Health Canada, and ICH.
Agency IQ
FEBRUARY 2, 2024
What We Expect the FDA to do in February and March 2024 (Updated) In this ongoing feature, AgencyIQ looks at public data to determine what the FDA is likely to do in the months ahead, including key deadlines, meetings, events, planned regulations, comment periods and more.
New Drug Approvals
DECEMBER 24, 2023
“Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen” Neurology and Therapy. S2CID 250989659. ^ “Eplontersen: FDA-Approved Drugs” U.S. Food and Drug Administration (FDA). Ionis Pharmaceuticals.
Let's personalize your content